Healthcare-focused investor Quadria Capital is targeting a 1.5x return on its $1.1 billion Fund III by early 2027. The firm plans to use India's stock markets to exit its investments in Maxivision Eye Hospitals and Aragen Life Sciences.
Detailed Coverage
Private equity firm Quadria Capital is moving to sell its stakes in several healthcare portfolio companies through public market listings in India. The firm aims to reach a 1.5x distributed paid-in capital—a measure of money returned to investors—from its $1.1 billion Fund III by early 2027. This move marks an effort to speed up cash returns to its investors.
IPO Pipeline and Exit Strategy
Quadria is currently preparing two of its portfolio companies, Maxivision Eye Hospitals and Aragen Life Sciences, for potential initial public offerings. This strategy follows the firm’s recent partial exit from NephroPlus. According to Quadria’s management, India’s public markets have become a key path for liquidity, shifting from the historical trend where the majority of exits were through sales to strategic buyers. While the firm still relies on strategic sales in Southeast Asian markets, the depth of the Indian capital market allows for faster exit options through the stock exchange.
Deployment and Sector Focus
Quadria Capital is managing the life cycle of its funds with a clear timeline. While its first fund has been fully exited, the second fund is expected to be fully divested by 2028. Meanwhile, the $1.1 billion Fund III, which closed in 2025, is currently 50% to 60% invested. The firm plans to increase this deployment to over 75% by the end of 2026. The investment strategy prioritizes healthcare delivery, medical technology, and pharmaceutical sectors. Within healthcare, the firm prefers single-specialty platforms over multi-specialty hospitals, citing potential for greater scale and operational efficiency. Specific medical fields such as oncology, gastroenterology, and nephrology remain priority areas, with the firm also looking to enter the critical care space.
Regional Allocation and Investor Impact
Quadria is concentrating more than half of its Fund III resources on the Indian market, with 50% to 55% of the total fund slated for local investments. The remaining capital is divided between ASEAN countries at 30% to 35%, and the GCC region at 10% to 15%. For investors in the broader Indian healthcare sector, the planned public listings of Maxivision and Aragen serve as significant events. The success of these listings will depend on prevailing market conditions, the financial health of the companies at the time of the IPO, and general demand for healthcare assets among public market participants. Investors should monitor future filings from these companies to understand their growth, debt levels, and profitability as they move closer to a public market debut.